output
19932025
most citedThe importance of transparency and reproducibility in artificial intelligence research

533 citations

Showing stat.MEShow all

6 papers · 1 filter

stat.ME2024

A comparison of methods for estimating the average treatment effect on the treated for externally controlled trials

Huan Wang, Fei Wu, Yeh-Fong Chen

While randomized trials may be the gold standard for evaluating the effectiveness of the treatment intervention, in some special circumstances, single-arm clinical trials utilizing…

stat.ME2023★ 3 cited

Sensitivity Analysis for Unmeasured Confounding in Medical Product Development and Evaluation Using Real World Evidence

Yixin Fang, Pallavi Mishra-Kalyani, Xiang Zhang +8

The American Statistical Association Biopharmaceutical Section (ASA BIOP) scientific working group on real-world evidence (RWE) has been making continuous, extended efforts towards…

stat.ME2022★ 2 cited

Modern Statistical Models and Methods for Estimating Fatigue-Life and Fatigue-Strength Distributions from Experimental Data

William Q. Meeker, Luis A. Escobar, Francis G. Pascual +4

Engineers and scientists have been collecting and analyzing fatigue data since the 1800s to ensure the reliability of life-critical structures. Applications include (but are not li…

stat.ME2022★ 134 cited

Practical considerations for specifying a super learner

Rachael V. Phillips, Mark J. van der Laan, Hana Lee +1

Common tasks encountered in epidemiology, including disease incidence estimation and causal inference, rely on predictive modeling. Constructing a predictive model can be thought o…

stat.ME2021★ 2 cited

BaySize: Bayesian Sample Size Planning for Phase I Dose-Finding Trials

Xiaolei Lin, Jiaying Lyu, Shijie Yuan +2

We propose BaySize, a sample size calculator for phase I clinical trials using Bayesian models. BaySize applies the concept of effect size in dose finding, assuming the MTD is defi…

stat.ME2020★ 1 cited

Hi3+3: A Model-Assisted Dose-Finding Design Borrowing Historical Data

Yunshan Duan, Sue-Jane Wang, Yuan Ji

Background -- In phase I clinical trials, historical data may be available through multi-regional programs, reformulation of the same drug, or previous trials for a drug under the…